
    
      A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of
      once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (BNP and
      NTproBNP), symptoms, health status, and quality of life in patients with chronic heart
      failure with reduced systolic function.
    
  